Myopia Control Methods
On this page
Direct answer
Myopia control exists because axial elongation, not blur alone, drives the lifetime risks of myopic maculopathy, retinal detachment and glaucoma — and each dioptre of myopia prevented is estimated to cut myopic maculopathy risk by roughly 40 per cent. The evidence-based toolkit has four arms: behavioural (outdoor light of at least about two hours daily, which slows onset), pharmacological (low-dose atropine — 0.01 per cent from ATOM2, with 0.05 per cent from the LAMP trial showing stronger effect), optical (orthokeratology slowing axial growth by roughly 30-60 per cent; myopia-control spectacle designs slowing progression by about half to two-thirds in trials), and correction discipline (never under-correct). Management is risk-stratified — early onset under 8-10 years, parental myopia, progression over 0.50-0.75 D per year — and monitored with cycloplegic refraction and axial length every six months.
What you must remember
- Why control: every dioptre avoided is associated with roughly 40 per cent lower myopic maculopathy risk; high myopia (beyond −5.00 to −6.00 D) carries the sight-threatening complications — macular degeneration, retinal detachment, glaucoma.
- Outdoor prescription: at least about two hours of daily outdoor light delays onset; indoor lighting does not substitute, and the effect is on incidence more than progression.
- Atropine arm: 0.01% established by ATOM2 (roughly half of untreated progression, minimal side effects); LAMP found 0.05% superior among low doses; rebound follows high-dose cessation, much less at low doses.
- Optical arm: orthokeratology — about 30-60% axial slowing; defocus multiple-segment (DIMS) and highly aspherical lenslet (HAL) spectacles — roughly 50-67% slowing over two years; standard bifocals and progressives give only modest (roughly 10-20%) benefit.
- Under-correction is harmful: deliberately weaker minus lenses accelerate progression in controlled studies — the old shop practice is refuted.
- Risk stratification for treatment: onset under about 8-10 years, two myopic parents, progression beyond roughly 0.75 D per year, or childhood myopia beyond about −3.00 D — treat actively rather than observe.
- Monitoring protocol: cycloplegic refraction plus axial length (biometry) every six months; axial elongation is the treatment target, since refraction alone is flattered by ortho-K's corneal flattening.
- Indian context: urban school myopia is rising steeply; outdoor time and low-dose atropine remain the most affordable public-health levers across the cost gradient of DIMS/HAL spectacles and ortho-K.
Managing a nine-year-old at risk
A nine-year-old presents at −2.50 D both eyes, both parents myopic, progression −0.75 D in the past year. Baseline: cycloplegic refraction, axial length (24.4 mm), topography, and a lifestyle audit — six school hours, three coaching hours indoors, 30 minutes outdoors. The plan stacks interventions: two hours of outdoor light daily, negotiated with the parents as homework; low-dose atropine 0.05% nightly (0.01% where the stronger dilution is unavailable) with a transparent discussion of light sensitivity and near blur; and myopia-control spectacles — DIMS or HAL design — in full correction, with ortho-K offered where the family can commit to follow-up and hygiene.
Six months later: axial growth 0.08 mm against an expected 0.20-0.25, refraction stable to −0.25 D, comfortable adaptation. The review continues to late adolescence with axial length as the honest yardstick — because if the family switches to ortho-K later, the flattened cornea will mask refraction while the biometer reports the truth. The exit conversation matters too: stopping atropine carries a mild rebound risk, so taper decisions wait until progression has flattened for a year.
Where candidates stumble
Quoting one number per intervention without mechanism — outdoor light and retinal dopamine, myopic peripheral defocus signalling the sclera to slow, atropine's dose-tiered effect. Reversing the under-correction answer is the single most penalised error: weaker glasses speed myopia. Confusing control with cure: axial length never shortens meaningfully; treatment brakes elongation. Forgetting practicalities — atropine's near blur in high accommodators, ortho-K's hygiene demands, the cost gradient in Indian practice. And the viva pairing: measure what you treat — axial length, not refraction alone, especially under orthokeratology.
Frequently asked questions
Why does each dioptre of myopia matter?
Roughly 40 per cent less myopic maculopathy risk is attributed to every dioptre avoided, alongside lower retinal detachment and glaucoma risk — the rationale for treating progression, not just blur.
What did the LAMP trial conclude about atropine doses?
That 0.05% atropine slows axial progression more than 0.025% and 0.01% over two years, all well tolerated — refining ATOM2's 0.01% foundation.
How much does outdoor time help, and for what?
At least about two hours daily delays myopia onset in children; its effect on established progression is weaker, so it pairs with, rather than replaces, atropine or defocus optics.
Which optical options control myopia best in trials?
Orthokeratology (about 30-60% axial slowing) and myopia-defocus spectacle or lens designs (roughly 50-67% progression slowing), far ahead of standard bifocals or progressives.
Why is under-correction no longer advised?
Randomised studies show under-corrected myopes progress faster than fully corrected ones — the practice is discredited and should be actively counselled against.